thymic-factor--circulating and Dysgammaglobulinemia

It was established that the use of thymalin in multimodality therapy of CHD patients suffering from attacks of angina pectoris of effort and at rest brought back to normal the state of cellular and humoral immunity, slowed down blood coagulation, decreased fibrinogen and FDP concentration, enhanced total euglobulin and Hageman-dependent fibrinolysis. A more rapid disappearance of the pain syndrome was noted in these patients as compared to those who had not received the drug.

Topics: Adult; Aged; B-Lymphocytes; Blood Coagulation; Coronary Disease; Dysgammaglobulinemia; Female; Humans; Immunoglobulins; Leukocyte Count; Male; Middle Aged; T-Lymphocytes; Thymus Hormones

Three children with IgA and IgE deficiency and T-cell defects (two related patients with ataxia telangiectasia and one with common variable immune deficiency) were treated with synthetic serum thymic factor (FTS) intravenously. A reduction in frequency and severity of infection was noted concomitantly with improvement in cell-mediated-immunity tests. Serum IgA, which was absent in two patients, appeared within 4 weeks of treatment and increased significantly in the third patient. Specific antibodies against vaccination antigens appeared for the first time or increased to titres higher than ever before. In two patients, transient interruption of FTS administration was followed by a regression of the immunological improvement, but this disappeared after the treatment was started again.

Topics: Adolescent; Antibody Formation; Ataxia Telangiectasia; Bronchiectasis; Child; Child, Preschool; Dysgammaglobulinemia; Female; Humans; IgA Deficiency; Immunity, Cellular; Immunoglobulin A; Immunoglobulin E; Injections, Intravenous; Male; Thymic Factor, Circulating; Thymus Hormones